SEC Tracker
Get the app

Oric Pharmaceuticals ORIC

Oric Pharmaceuticals (Oric) announced the resignation of its Chief Executive Officer, effective immediately. This unexpected leadership change could signal strategic shifts or operational challenges that investors should monitor closely, as the company's pipeline of oncology drug candidates is critical to its future growth and valuation.

Form
8-K
Filed
Importance
Major

Open in the appGet the appView on EDGAR

Get an email when Oric Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Geron GERN public float $861M, Jun 30, 2025
  2. Intellia Therapeutics NTLA public float $869M, Jun 30, 2025
  3. Wave Life Sciences WVE public float $851M, Jun 30, 2025
  4. CorMedix CRMD public float $910M, Jun 30, 2025
  5. Niagen Bioscience NAGE public float $814M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.